This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Khanna D, Yan X, Tashkin DP, Furst DE, Elashoff R, Roth MD, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Clements PJ, Scleroderma Lung Study Group.Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the Scleroderma Lung Study. Arthritis and Rheumatism 56: 1676-1684, No. 5, May 2007
Rights and permissions
About this article
Cite this article
Cyclophosphamide improves QOL in scleroderma lung disorder. Pharmacoecon. Outcomes News 531, 10 (2007). https://doi.org/10.2165/00151234-200705310-00019
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200705310-00019